{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsing-remitting+Multiple+Sclerosis&page=9",
    "query": {
      "condition": "Relapsing-remitting Multiple Sclerosis",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 283,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsing-remitting+Multiple+Sclerosis&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsing-remitting+Multiple+Sclerosis&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T23:15:56.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00594087",
      "title": "Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis",
        "Sleep Initiation and Maintenance Disorders",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "eszopiclone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-12",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2009-01-05",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594087"
    },
    {
      "nct_id": "NCT00324506",
      "title": "Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil (CellCept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 43,
      "start_date": "2006-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 3,
      "location_summary": "Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324506"
    },
    {
      "nct_id": "NCT00235989",
      "title": "Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta 1b (Betaseron, BAY86-5046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2003-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235989"
    },
    {
      "nct_id": "NCT07222618",
      "title": "\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Primary Progressive",
        "MS (Multiple Sclerosis)",
        "MS",
        "Multiple Sclerosis (MS) Secondary Progressive"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-10-01",
      "completion_date": "2028-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222618"
    },
    {
      "nct_id": "NCT02652091",
      "title": "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1b (Betaseron, BAY86-5046)",
          "type": "DRUG"
        },
        {
          "name": "BETACONNECT device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2016-02-05",
      "completion_date": "2017-09-13",
      "has_results": false,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 23,
      "location_summary": "Cullman, Alabama • Boca Raton, Florida • New Port Richey, Florida + 19 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652091"
    },
    {
      "nct_id": "NCT00202982",
      "title": "A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapse-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "glatiramer acetate 20 mg",
          "type": "DRUG"
        },
        {
          "name": "glatiramer acetate 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2003-08",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-01-14",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Oceanside, California • Atlanta, Georgia + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Northbrook",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00202982"
    },
    {
      "nct_id": "NCT04880577",
      "title": "Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-15",
      "completion_date": "2025-02-14",
      "has_results": false,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04880577"
    },
    {
      "nct_id": "NCT01226745",
      "title": "Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ONO-4641",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 340,
      "start_date": "2010-10",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226745"
    },
    {
      "nct_id": "NCT01158183",
      "title": "Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "BAY86-5046_Interferon-beta-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 226,
      "start_date": "2007-07",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2010-07-08",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 27,
      "location_summary": "Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more",
      "locations": [
        {
          "city": "Many Locations",
          "state": "Alabama"
        },
        {
          "city": "Many Locations",
          "state": "California"
        },
        {
          "city": "Many Locations",
          "state": "Colorado"
        },
        {
          "city": "Many Locations",
          "state": "Florida"
        },
        {
          "city": "Many Locations",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158183"
    },
    {
      "nct_id": "NCT03594487",
      "title": "Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "FMP30 Donor Stool",
          "type": "DRUG"
        },
        {
          "name": "Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool",
          "type": "PROCEDURE"
        },
        {
          "name": "Observational Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Jeffrey Gelfand",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-11-16",
      "completion_date": "2024-12-16",
      "has_results": true,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-22T23:15:56.357Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594487"
    }
  ]
}